VatanicVatanic

JA
EN
FOR OWNER
close

iPS Cells,
To be the heart of animal regenerative medicine.
Firstly with dogs.

JA
EN
CONTACTCONTACT

iPS細胞を動物再生医療の真ん中にまずは犬から。

iPS Cells,
To be the heart of animal regenerative medicine.
Firstly with dogs.

We want to save as many animal lives as possible.
In order to fulfill such goal, we apply regenerative medicine that is now being put to practical use in humans to animals.
For this purpose, we utilize our proprietary animal iPS cell technology that enables us to deliver high-quality regenerative medicine unlike relying on living animal donors. Hence, we hope iPS cells to be the heart of animal regenerative medicine.

We started development of iPS cells-derived regenerative medicine products, firstly with dogs.

And, safety is the first and foremost important thing for bringing regenerative medicine to animals.

We also value the security of veterinarians and people whose partner animals are treated.

We grow this technology in the same way as we hold the passion to nurture our dogs, cats, and other precious partner animals, and aim our goal that is to create a society in which both people and animals can live happily.

Originating from unique canine iPS cells
toward practical application of regenerative medicine products

The technology to establish iPS cell lines in dogs and other animals was established by a joint research project between Nihon University and Keio University.

A unique set of reprogramming factors is transfected into cells without the use of viruses, resulting in canine iPS cells that can maintain their pluripotency for a long period of time and are suitable for clinical applications. iPS cells can be differentiated into various types of cells and can be used to make a variety of regenerative medical products. Starting with dogs, Vetanic will induce the differentiation of canine mesenchymal stem cells (MSCs) from canine iPS cells, and aiming for the approval from the Ministry of Agriculture, Forestry and Fisheries as a qualified pharmaceutical product.

Our Technology

  • Fundamental technology

    Canine iPS Cells
    - Successfully established as a suitable grade for clinical applications.

    So called "Clinical grade" canine iPS cells
    was produced by resolving the technical issues to date.

    For more information

  • Core product

    Canine mesenchymal stem cells (MSCs)
    was successfully induced

    Inducing canine mesenchymal stem cells (MSCs) from canine iPS cells into a cell therapy product compliant with the Pharmaceuticals and medical devices Law.

    For more information
Originating from Unique Canine iPS Cells Toward Practical Application of Regenerative Medicine ProductsOriginating from Unique Canine iPS Cells Toward Practical Application of Regenerative Medicine Products
私達は、人も動物も幸せになって欲しいと願っています。私達は、人も動物も幸せになって欲しいと願っています。

Implementation of accessible
and sustainable regenerative medicine from iPS cells.

In order to spread the animal regenerative medicine, we believe that this therapy should be an easy-to-use treatment option for many families, and it should be performed without placing a burden on the donor.

Since iPS cells can be cultured in large quantities, once they are produced, donor-dependent free regenerative medicine becomes possible. Moreover, the use of iPS cells will enable the development of a variety of regenerative medical products. We want to implement accessible and sustainable regenerative medicine by utilizing iPS cells.

About us

NEWS

  • 2024.11.30NEWS

    The patent for the establishment of animal iPS cells has been granted in Japan.

    We are pleased to announce that we have been granted a patent in Japan for the foundational technology behind the establishment of animal iPS cells (Patent No. 7591219). This patent, based on the results of joint research by Keio University and Nihon University, was filed jointly, and Vetanic holds an exclusive license to its utilisation.

    Establishing iPS cells (induced pluripotent stem cells) in various animal species other than mice has long been recognised as a challenge. These species, known as “Resistance to pluripotency induction”, contain many animals that are closely connected to humans, such as dogs and cats. Our technology founders – Professor and Director Hideyuki Okano of the Keio University Regenerative Medicine Center, Professor Seiji Shiozawa of the Disease Model Research Center at Kurume University School of Medicine, and Professor and Director Kazuya Edamura of the Nihon University Animal Medical Center at Nihon University College of Bioresource Sciences – have developed a proprietary method to stably induce iPS cells in these animal species and establish cell lines suitable for clinical applications.

    This patent grant confirms the patentability of this method within Japan. Moving forward, we aim to secure patent approval for this technology in other countries as well.

    Technical Details:
    Establishing methods to produce iPS cells from various animal species – a critical resource forming the foundation of cell engineering using stem cells.

    https://www.keio.ac.jp/ja/press-releases/2021/4/2/28-78924

  • 2024.11.11NEWS

    Announcement of Basic Agreement on Business Partnership with Kojin Bio Co., Ltd. for Product Development

    We are pleased to announce that we have entered into a basic agreement on a business partnership with Kojin Bio Co., Ltd. (TSE Growth 177A, President: Takahito Nakamura) for “the development of animal iPS cell-derived regenerative medicine and related research-use products.”

    Kojin Bio is a leading company in the regenerative medicine field, expanding its business domestically and internationally through the unique development of cell culture media and contract services for cell processing. Additionally, the company has engaged in pioneering research efforts in the field of veterinary medicine.

    Through this partnership, we accelerate research and development, promote the manufacturing of higher-quality product, and expedite the early acquisition of marketing approval of our cell therapy product to achieve our goal of “global-standard animal regenerative medicine.” Furthermore, we collaborate with Kojin Bio to develop various animal iPS cell-derived cells for the purpose of basic research with their accumulated expertise.

    Please refer to the PDF below for further details. (JAPANESE language only)

    241111 Vetanic_コージンバイオ業務支援 PRダウンロード

  • 2024.04.10ARTICLE

    The article introducing Vetanic has been made available at Nikkei Biotechnology & Business Online on the 5th April 2024.

    Please refer the online article from below URL link. (available to the subscription members only)

    Nikkei Biotechnology & Business, 5th April 2024　特集連動◎多様化と高度化が進む動物薬　「Vetanic、イヌ・ネコのiPS細胞作製技術で複数疾患に対する再生医療等製品を開発」

News

Learn more about iPS cells and animal regenerative medicine

FOR OWNER
CONTACT